Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-SN201 in advanced solid tumors
NCT06184035Phase 2Recruiting
- Sponsor
- Spago Nanomedical AB
- Start
- Dec 2023
- Primary completion
- Dec 2027
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu-177 SN201 in solid tumor, sponsored by Spago Nanomedical AB. Started Dec 2023; status: recruiting.
02
Drugs
lutetium Lu-177 SN201
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06184035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06184035.